Clinical Trials
14 trialsActive not recruiting × Carcinoma, Non-Small-Cell Lung × 130-nm albumin-bound paclitaxel × Clear all
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT04015778 2026-05-20
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Guangdong Association of Clinical Trials
Phase 2 Active not recruiting
NCT03819465 2026-05-12
MAGELLAN
AstraZeneca
Phase 1 Active not recruiting
NCT02495896 2026-04-29
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT05867121 2026-04-27
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
Genentech, Inc.
Phase 1 Active not recruiting
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT03774732 2026-02-25
NIRVANA-LUNG
UNICANCER
Phase 3 Active not recruiting
NCT05502237 2026-01-30
STAR-121
Gilead Sciences
Phase 3 Active not recruiting
NCT06212752 2025-11-12
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04623775 2025-10-20
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05722015 2025-09-11
MK-3475A-D77
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03893955 2025-08-12
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT05919537 2025-04-18
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
Hummingbird Bioscience
Phase 1 Active not recruiting
NCT04956692 2024-12-03
MK-3475-A86
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting